May 12, 2025

Democratizing Liquid Biopsy-Based Precision Oncology Biomarkers in the United States

Four national thought leaders discuss the latest advancements and practical applications of liquid biopsy in cancer diagnostics and treatment

The Pathologist

May 09, 2025

GLP-1 Receptor Agonists May Reduce Risk of Hematologic Malignancies

New research finds GLP-1 receptor agonists significantly reduce hematologic malignancy risk in patients with type 2 diabetes compared to insulin therapy, with up to 81% lower risk for certain malignancies.

Conexiant

May 09, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

May 09, 2025

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at...

The ASCO Post

May 09, 2025

FDA Clears First At-Home HPV Test

"This approval is not just about an innovative new product; it’s about finally giving women an option that makes sense for their lives."

Conexiant

May 09, 2025

Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?

With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which pa...

The ASCO Post

May 09, 2025

Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer

Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Associ...

The ASCO Post

May 09, 2025

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Two pivotal phase III trials presented at the 2024 ASH Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia, offering potentiall...

The ASCO Post

May 09, 2025

Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, accepted an award and gave remarks during the meeting’s Opening Ceremony.

The ASCO Post